Cue Biopharma, Inc.

CUE

$18.76

Name : Cue Biopharma, Inc.

Sector : Healthcare

Industry: Biotechnology

Mark. Cap: $136,280,416.00

EPSttm : -29.59

Cue Biopharma, Inc.

$18.76

6.85%

$1.38

CUE — Price & Float Short

—— Fair value ★ EPS beat ★ EPS miss —— Target Price

Float Short %

13.59

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

EPS Last/This Y

-16.61

EPS This/Next Y

17.57

Price

Target Price

Analyst Recom

Performance Q

-38.33

Upside

-5,137.3%

Beta

2.81

Ticker: CUE

22 items of 1

Date	Symbol	Latest	P/C OI	P/C Vol	Total OI
2026-10-12	CUE	24.5	N/A	N/A	0
2026-10-13	CUE	19.54	N/A	N/A	0
2026-10-14	CUE	18.33	N/A	N/A	0
2026-10-15	CUE	18.9	N/A	N/A	0
2026-10-16	CUE	16.71	0.06	0.00	383
2026-10-19	CUE	16.1	0.06	0.00	383
2026-10-20	CUE	17.12	0.06	0.00	383
2026-10-21	CUE	19.07	0.06	0.00	383
2026-10-22	CUE	18.83	0.06	0.00	383
2026-10-23	CUE	18.43	0.06	0.00	383
2026-10-26	CUE	18.42	N/A	N/A	0
2026-10-27	CUE	18.09	N/A	N/A	0
2026-10-28	CUE	21.31	N/A	N/A	0
2026-10-29	CUE	21.11	N/A	N/A	0
2026-10-30	CUE	20.81	N/A	N/A	0
2026-11-02	CUE	19.11	N/A	N/A	0
2026-11-03	CUE	20.5	N/A	N/A	0
2026-11-04	CUE	19.72	N/A	N/A	0
2026-11-05	CUE	18.05	N/A	N/A	0
2026-11-06	CUE	18.58	N/A	N/A	0
2026-11-09	CUE	20.715	N/A	N/A	0
2026-11-10	CUE	19.17	N/A	N/A	0
Date	Symbol	Latest	P/C OI	P/C Vol	Total OI

22 items 1 of 1

22 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2026-10-12	CUE	24.76	-	-	-25.01
2026-10-13	CUE	19.50	-	-	-25.01
2026-10-14	CUE	18.38	-	-	-25.01
2026-10-15	CUE	18.78	-	-	-25.01
2026-10-16	CUE	16.79	-	-	-25.01
2026-10-19	CUE	16.10	-	-	-25.01
2026-10-20	CUE	16.10	-	-	-25.01
2026-10-21	CUE	17.18	-	-	-25.01
2026-10-22	CUE	18.85	-	-	-25.01
2026-10-23	CUE	18.59	-	-	-25.01
2026-10-26	CUE	18.38	-	-	-25.01
2026-10-27	CUE	18.20	-	-	-25.01
2026-10-28	CUE	21.26	-	-	-25.01
2026-10-29	CUE	21.40	-	-	-25.01
2026-10-30	CUE	20.58	-	-	-25.01
2026-11-02	CUE	19.22	-	-	-25.01
2026-11-03	CUE	20.99	-	-	-25.01
2026-11-04	CUE	19.79	-	-	-25.01
2026-11-05	CUE	18.01	-	-	-25.01
2026-11-06	CUE	18.58	-	-	-25.01
2026-11-09	CUE	20.40	-	-	-25.01
2026-11-10	CUE	19.00	-	-	-25.01
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

22 items 1 of 1

21 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2026-10-12	CUE	-6.59	19.30	11.27
2026-10-13	CUE	-6.59	19.30	12.09
2026-10-14	CUE	-4.78	19.30	12.09
2026-10-15	CUE	-5.65	19.30	12.09
2026-10-16	CUE	-5.65	19.30	12.09
2026-10-19	CUE	-5.65	20.59	12.04
2026-10-20	CUE	-5.70	20.59	12.04
2026-10-21	CUE	-5.70	20.59	12.04
2026-10-22	CUE	-5.70	20.59	12.04
2026-10-23	CUE	-5.70	20.59	12.04
2026-10-26	CUE	-5.70	20.72	12.04
2026-10-27	CUE	-5.70	20.72	13.59
2026-10-28	CUE	-5.70	20.72	13.59
2026-10-29	CUE	-5.70	20.72	13.59
2026-10-30	CUE	-5.70	20.72	13.59
2026-11-02	CUE	-5.70	20.66	13.59
2026-11-03	CUE	-5.70	20.66	13.59
2026-11-05	CUE	-5.70	20.66	13.59
2026-11-06	CUE	-5.70	20.66	13.59
2026-11-09	CUE	-5.70	20.66	13.59
2026-11-10	CUE	-5.70	20.66	13.59
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

21 items 1 of 1

Last Quarter Act. EPS

Avg. EPS Est. Current Quarter

-2.24

Avg. EPS Est. Next Quarter

-1.76

Insider Transactions

-5.7

Institutional Transactions

20.66

Beta

2.81

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

96.6

Max Drawdown 5-Year %

-99

Target Price

P/E

Forward P/E

PEG

P/S

3.62

P/B

42.47

P/Free Cash Flow

EPS

-27

Average EPS Est. Cur. Y

-25.01

EPS Next Y. (Est.)

-7.44

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-435.83

Relative Volume

0.51

Return on Equity vs Sector %

-100

Return on Equity vs Industry %

-100

EPS 1 7Days Diff

EPS 1 30Days Diff

-3.56

EBIT Estimation

◆ CUE Healthcare

$18.76

📉

Swing / Pullback

Buy the dip on strong trends

N/A

WEAK

Trend

2/20

Pullback

17/25

Volume

11/15

Valuation

12/20

TP/AR

2/10

Options

0/10

RSI

43.7

Range 1M

25.7%

Sup Dist

2.3%

🚀

Momentum Growth

Ride accelerating trends

N/A

WEAK

Momentum

1/25

Growth

13/30

Estimates

0/20

Inst/Vol

5/15

Options

0/10

EPS Yr

-197.7%

EPS NY

70.2%

52W%

35.3%

💎

Long-Term Value

Quality companies, undervalued

N/A

WEAK

🟢 BUY +369.1% upside

Quality

6/30

Valuation

16/30

Growth

8/25

Stability

2/10

LT Trend

0/5

Upside

+369.1%

Quality

CUE — P/E HistoricalBiotechnology

Cue Biopharma, Inc.

Sector: Healthcare

Industry: Biotechnology

Employees: 29

Cue Biopharma, Inc., a clinical-stage therapeutics company, focuses on developing various therapies for immunological disorders. The company's lead asset is CUE-221, an anti-IgE antibody with a dual-mechanism of action currently in Phase 2 development for allergic diseases. It also developed the Immuno-STAT platform, which targets disease-specific T cells in vivo without broad immune modulation. The company's lead autoimmune candidate is CUE-401, a bifunctional IL-2 and TGF-B program that is advancing towards Phase 1 development to regulate inflammation and drive Treg-mediated tolerance. The company was formerly known as Imagen Biopharma, Inc. and changed its name to Cue Biopharma, Inc. in October 2016. Cue Biopharma, Inc. was incorporated in 2014 and is headquartered in Boston, Massachusetts.

CUE

Latest News

—

Caricamento notizie per CUE…

stock quote shares CUE – Cue Biopharma Inc Stock Price stock today

news today CUE – Cue Biopharma Inc stock forecast ,stock prediction 2023 2024 2025

marketwatch CUE – Cue Biopharma Inc yahoo finance google finance

stock history CUE – Cue Biopharma Inc invest stock market

stock prices CUE premarket after hours

ticker CUE fair value insiders trading

Float Short %

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

EPS Last/This Y

EPS This/Next Y

Price

Target Price

Analyst Recom

Performance Q

Upside

Beta

Ticker: CUE

Last Quarter Act. EPS​

Avg. EPS Est. Current Quarter

Avg. EPS Est. Next Quarter

Insider Transactions

Institutional Transactions

Beta

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

Max Drawdown 5-Year %

Target Price

P/E

Forward P/E

PEG

P/S

P/B

P/Free Cash Flow

EPS

Average EPS Est. Cur. Y​

EPS Next Y. (Est.)

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

Return on Equity vs Sector %

Return on Equity vs Industry %

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

Latest News

Last Quarter Act. EPS

Average EPS Est. Cur. Y